Management Team Bruce C. Cozadd Executive Chairman Bruce Cozadd joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Mr. Cozadd served as a consultant to companies in the biopharmaceutical industry. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. Mr. Cozadd serves on the boards of Cerus Corporation, a biopharmaceutical company; Threshold Pharmaceuticals, a biotechnology company; and The Nueva School and Stanford Hospital and Clinics, both non-profit organizations. Samuel R. Saks, MD Chief Executive Officer Samuel Saks, M.D., joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Dr. Saks was Company Group Chairman of ALZA Corporation and served as a member of the Johnson & Johnson Pharmaceutical Group Operating Committee. From 1992 until 2001, he held various positions with ALZA Corporation, most recently as its Chief Medical Officer and Group Vice President, where he was responsible for clinical and commercial activities. Dr. Saks received a B.S. and an M.D. from the University of Illinois. Dr. Saks serves on the board of Trubion Pharmaceuticals and Cougar Biotechnology. Robert M. Myers President Robert Myers joined Jazz Pharmaceuticals at its inception and was appointed as Jazz Pharmaceuticals’ President in March 2007. From 2003 until 2007, Mr. Myers served as Jazz Pharmaceuticals’ Executive Vice President and Chief Business Officer. From 2002 until 2003, Mr. Myers served as Executive Vice President, Pharmaceuticals at Exelixis, Inc., a biotechnology company. He previously held various positions with ALZA Corporation from 1992 to 2001, most recently as its Senior Vice President, Commercial Development. In this role, he was responsible for ALZA Corporation’s corporate development, mergers and acquisitions, new product planning and corporate planning. Mr. Myers received B.S. and M.S. degrees from Stanford University and an M.B.A. from the Stanford Graduate School of Business. He serves on the Board of Cogentus Pharmaceuticals. Management Team Carol A. Gamble Senior Vice President, General Counsel & Corporate Secretary Carol Gamble was appointed as Jazz Pharmaceuticals’ Senior Vice President in 2004 and has served as Jazz Pharmaceuticals’ General Counsel and Corporate Secretary since 2003. From 2000 to 2002, she served as General Counsel and Corporate Secretary of Aerogen, Inc., a biopharmaceutical company acquired by Nektar Therapeutics. From 1988 to 2000, she held various positions with ALZA Corporation, most recently as its Senior Vice President and Chief Corporate Counsel. Ms. Gamble received a B.S. from Syracuse University and a J.D. from the University of California, Berkeley, Boalt Hall. Janne L. T. Wissel Senior Vice President, Chief Regulatory Officer & Chief Compliance Officer Janne Wissel has served as Jazz Pharmaceuticals’ Senior Vice President of Development since 2004. From 2003 to 2004, she served as Jazz Pharmaceuticals’ Vice President of Development. From 1981 to 2003, she held various positions at ALZA Corporation, most recently as its Senior Vice President, Operations, with responsibility for ALZA Corporation’s global regulatory, quality, general operations and manufacturing activities. She has led the development, registration and launch of more than 20 pharmaceutical products in the neurology, pediatric psychiatry, endocrinology, urology and oncology areas. Ms. Wissel received a B.S. from the University of California, Davis and an M.B.A. from the University of Phoenix. Michael DesJardin Senior Vice President, Product Development Michael DesJardin was appointed as Jazz Pharmaceuticals’ Senior Vice President, Product Development in May 2008. Mr. DesJardin joined Jazz Pharmaceuticals in July 2004 as Vice President, Product Development, with over 25 years of industry experience. Mr. DesJardin previously served in positions of increasing responsibility at ALZA Corporation starting in 1995, most recently as Executive Director for Implant R&D. In addition, Mr. DesJardin worked for 15 years in chemical development, with several assignments in API manufacturing at Dow Chemical and Marion Merrell Dow. Mr. DesJardin has led technical development and commercial manufacturing for chemical and pharmaceutical products which incorporated several drug delivery technologies, including oral, implantable, and injection systems. Mr. DesJardin received a Bachelor of Science in Chemical Engineering from the University of California, Berkeley and is a registered Professional Engineer in the State of California. Management Team Mark G. Eller, Senior Vice President, Research & Clinical Development Mark Eller was appointed as Jazz Pharmaceuticals’ Senior Vice President, Research and Clinical Development in May 2008. Dr. Eller joined Jazz Pharmaceuticals in May 2005 as Vice President, Research. Prior to joining Jazz Pharmaceuticals, he was Vice President, Clinical Pharmacology at Quintiles, a position he held beginning in January 2001. From 1988 until joining Quintiles, Dr. Eller served in positions of increasing responsibility at Hoechst Marion Roussel (now Sanofi-Aventis). Prior to joining HMR, he held positions with The Upjohn Company and the University of Cincinnati College of Pharmacy. Dr. Eller holds a Ph.D. in Pharmaceutics from The University of Iowa and received his B.S. in Pharmacy from The University of Iowa College of Pharmacy. Diane R. Guinta, Ph.D. Vice President, Clinical Research & Development Diane R. Guinta, Ph.D. joined Jazz Pharmaceuticals in July 2006. For the six years before joining the company, Dr. Guinta acted as a consultant in the clinical development field. From 1986 – 1997, she served in positions of increasing responsibility in the clinical development, program management, and clinical operations areas at ALZA Corporation, most recently as Senior Director, Clinical Operations and Senior Research Fellow. Dr. Guinta holds a Ph.D. in Microbiology from the University of Chicago. She received her B.S. in Biology from Trinity College in Hartford, Connecticut and completed her post-doctoral training at Stanford University School of Medicine. Dr. Guinta has served as the Chair of the Board of Trustees at Castilleja School, a non-profit corporation in Palo Alto, California and has taught middle school science to underserved students from East Palo Alto at St. Elizabeth Seton School, also in Palo Alto. P. J. Honerkamp Vice President, Deputy General Counsel P.J. Honerkamp joined Jazz Pharmaceuticals in 2004. From 2004 to 2008, Mr. Honerkamp acted in roles of increasing responsibility in the legal department, and is presently responsible for corporate legal matters including licensing and acquisitions, SEC reporting, clinical trials, commercial contracts, and debt and equity offerings. Prior to joining the company, Mr. Honerkamp was an attorney at the law firm of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP where he focused on corporate and securities law; private, public and commercial financings; mergers and acquisitions; licensing and strategic transactions; and venture fund formations. Mr. Honerkamp received his BA from Davidson College and his JD from Harvard Law School. Management Team Jason Levin Vice President, Corporate Development Jason Levin joined Jazz Pharmaceuticals in 2003 and is currently responsible for Corporate Strategy, Licensing & Acquisitions, and New Product Planning. From 2004 to 2007 he was Jazz Pharmaceuticals’ Executive Director of Licensing & Acquisitions. Mr. Levin brings more than 17 years of experience in the life sciences industry. Prior to joining Jazz Pharmaceuticals, Mr. Levin served as Director, Business Development at ALZA Corporation, a wholly owned subsidiary of Johnson and Johnson. In this role, Mr. Levin participated in ALZA’s drug delivery technology in-licensing and out-licensing efforts. Previously, he was responsible for business development at an early stage medical diagnostics company in Austin, Texas, following four years in The Woodlands, Texas as a scientist at GeneMedicine, Inc. (now Valentis, Inc.) Mr. Levin received an M.B.A. from the University of Texas, McCombs Graduate School of Business, and a Bachelor’s degree from the University of California, San Diego. He has been a member of the Licensing Executive Society since 2000 and serves as an advisor to several early stage biopharmaceutical companies. Edwin W. Luker Vice President, Sales Ed Luker joined Jazz Pharmaceuticals in October 2005. Mr. Luker was most recently National Field Sales Director, Pain Management, for McNeil Consumer & Specialty Pharmaceuticals, a division of Johnson & Johnson. In this role, he led the sales launch strategy for FLEXERIL® 5mg. Previously, he held various roles at ALZA Corporation, including Area Business Director of CNS, where he co-led the salesforce which launched CONCERTA®. Prior to joining ALZA, Mr. Luker served in various sales and marketing management positions with VIVUS, Inc., where he helped build the launch team for MUSE®; International Rehabilitative Sciences and Syntex Laboratories. He holds